Sign In |Help & Support
ALL SECTORS
  • ALL SECTORS
  • GB(National Standard)
  • CB(Shipping)
  • CECS(Engineering Construction)
  • CJ(Urban Construction)
  • CY(News and Publication)
  • DB(Provincial Standard)
  • DL(Electricity & Power)
  • DZ(Geology & Mineralogy)
  • FZ(Spinning & Textile)
  • GA(Public Security)
  • HB(Aviation)
  • HG(Chemical Industry)
  • HJ(Environmental Protection)
  • JB(Machinery)
  • JC(Building Materials)
  • JG(Building & Construction)
  • JJ(Metering)
  • JT(Highway & Transportation)
  • LY(Forestry)
  • MT(Coal)
  • NB(Energy)
  • NY(Agriculture)
  • QB(Light Industry)
  • QC(Automobile & Vehicle)
  • QJ(Aerospace)
  • SH(Petrochemical)
  • SJ(Electronics)
  • SL(Water Resources)
  • SN(Commodity Inspection)
  • SY(Oil & Gas)
  • TB(Railway & Train)
  • YB(Ferrous Metallurgy)
  • YC(Tobacco)
  • YD(Telecommunication)
  • YY(Medical Device)
Database: 365,228(8 Aug 2026)
electromagnetic shielding construction acceptance sauna weather intelligent optical distribution network management system introductionthis standard
GB/T 39381.1-2020 in English

GB/T 39381.1-2020 in English

VALID

Cardiovascular implants—Vascular device-drug combination products—Part 1:General requirements

  • Issued on:2020-11-19
  • Implemented on:2021-12-01
  • File Format:PDF
  • Delivery:Via email within 5 business days
Price(USD): $430.00
$418.00

《GB/T 39381.1-2020心血管植入物 血管药械组合产品 第1部分:通用要求》由TC110(全国外科植入物和矫形器械标准化技术委员会)归口,TC110SC2(全国外科植入物和矫形器械标准化技术委员会心血管植入物分会)执行,主管部门为国家药品监督管理局。


Introduction

Analysis of the core content of the standard

Technical dimensions Key requirements Test methods
Drug content consistency Intra-batch difference ≤15% HPLC/UV spectrophotometry
Drug release characteristics 80% drug release time control In vitro dissolution test
Biocompatibility In compliance with GB/T 16886 series Cytotoxicity/sensitization test

Technology Evolution Background

This standard adopts ISO 12417-1:2015, adjusts the reference document system according to China's regulatory requirements, and adds special requirements such as solvent residue. The technology of vascular drug-device combination products has evolved from simple mechanical treatment to targeted drug delivery, which requires a balance between the mechanical properties of the device and the controlled release characteristics of the drug.


Implementation recommendations

Case: In the development of drug-eluting stents, it is recommended to use accelerated aging tests (40℃/75%RH) to verify the stability of the coating. At the same time, the following should be carried out:

  • Microscopic examination of coating integrity after stent expansion
  • 28-day animal experiment to evaluate the degree of endothelialization
  • LC-MS detection of degradation products

Special considerations

For products containing degradable matrices, additional attention should be paid to:

  1. Matching of degradation rate with drug release curve
  2. Biocompatibility of degradation products
  3. Effect of sterilization method on material properties (e.g., γ irradiation may change polymer crystallinity)

Sample only — not a preview of GB/T 39381.1-2020
Page: 1 / 0
100%

Loading PDF document...

Error loading PDF. Please make sure the file is valid and try again.

We also recommend